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Abstract Orexins A and B are newly discovered neuro-
peptides with pleiotropic activity. They signal through two G
protein-coupled receptors: OX1 and OX2.I nt h i ss t u d y ,w e
examined the expression of orexin receptors and effects of
the receptors’ activation on cyclic AMP formation in the
primary neuronal cell cultures from rat cerebral cortex. Both
types of orexin receptors were expressed in rat cortical
neurons; the level of OX2R was markedly higher compared
to OX1R. Orexin A (an agonist of OX1Ra n dO X 2R) and
[Ala
11-D-Leu
15]orexin B (a selective agonist of OX2R) did
not affect basal cyclic AMP formation in the primary
neuronal cell cultures. Both peptides (0.001–1 μM)
inhibited, in a concentration-dependent manner and IC50
values in low nanomolar range, the increase in the nucleotide
production evoked by forskolin (1 μM; a direct activator of
adenylyl cyclase), pituitary adenylate cyclase-activating
polypeptide (PACAP27; 0.1 μM), and vasoactive intestinal
peptide (VIP; 3 μM). Effects of orexin A on forskolin-,
PACAP27-, and VIP-stimulated cyclic AMP synthesis were
blocked by TCS OX2 29 (a selective antagonist of OX2R),
and unaffected by SB 408124 (a selective antagonist of
OX1R). Pretreatment of neuronal cell cultures with pertussis
toxin (PTX) abolished the inhibitory action of orexin A on
forskolin- and PACAP-stimulated cyclic AMP accumulation.
It is suggested that in cultured rat cortical neurons orexins,
acting at OX2 receptors coupled to PTX-sensitive Gi protein,
inhibit cyclic AMP synthesis.
Keywords Orexin.Hypocretin.Orexin receptors.Cyclic
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cortex.Rat
Abbreviations
FOR Forskolin
GFAP Glial fibrillary acidic protein
IBMX 3-Isobuthyl-1-methyxanthine
OX1R Type 1 orexin receptor
OX2R Type 2 orexin receptor
PACAP Pituitary adenylate cyclase-activating
polypeptide
PTX Pertussis toxin
SB 408124 N-(6,8-difluoro-2-methyl-4-quinolinyl)-N′-
[4-(dimethylamino)phenyl]urea
TCS OX2 29 (2S)-1-(3,4-dihydro-6,7-dimethoxy-
2(1H)-isoquinolinyl)-3,3-dimethyl-2-
[(4-pyridinylmethyl)amino]-1-butanone
hydrochloride
VIP Vasoactive intestinal peptide
Introduction
Orexins (orexins A and B), also known as hypocretins
(hypocretins 1 and 2), are multifunctional neuropeptides
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DOI 10.1007/s12031-011-9526-2discovered by two independent research groups in 1998
using orphan receptor technologies (Sakurai et al. 1998)
and subtractive cDNA cloning (de Lecea et al. 1998). Both
orexins are derived from a common precursor, preproor-
exin, by proteolytic cleavage (Sakurai et al. 1998, 1999),
and share 46% aminoacid identity in humans (de Lecea and
Sutcliffe 1999). Although production of the peptides is
restricted to a discrete population of neurons in the lateral
and posterior hypothalamus, the projection fields of these
neurons have been identified in numerous brain regions,
including the cortex, thalamus, hypothalamus, brain stem,
and spinal cord (Matsuki and Sakurai 2008). This diffuse
projection pattern suggests that the orexin system regulates
multiple complex physiological functions. Indeed, accumu-
lated experimental evidence indicate an involvement of
orexins in the regulation of vigilance and sleep/wake cycle,
feeding, appetite, reward seeking, and energy homeostasis
(Kukkonen et al. 2002; Matsuki and Sakurai 2008; Carter et
al. 2009; Kodatek and Cai 2010). The peptides also control
hypothalamo–pituitary–adrenal axis and functions of mis-
cellaneous peripheral organs, including heart, kidney,
thyroid, lung, testis, ovaries, and adipose tissues (Voisin et
al. 2003; Spinazzi et al. 2006; Heinonen et al. 2008;
Okumura and Takakusaki 2008; Kagerer and Jöhren 2010).
The loss or dysfunction of orexin neurons has been shown
to cause human and animal narcolepsy [e.g., (Chemelli et
al. 1999; Lin et al. 1999; Geraschenko et al. 2001;
Thannickal et al. 2003; Mieda et al. 2004)].
Orexins orchestrate their diverse central and peripheral
effectsviatwomembrane-boundGprotein-coupledreceptors,
OX1Ra n dO X 2R( S a k u r a ie ta l .1998). These receptors
share a 64% identity to each other in their amino acid
sequences. Studies in heterologous expression systems have
demonstrated that OX2R has an equal affinity for both
orexins A and B, whereas OX1R has approximately tenfold
greater affinity for orexin A than for orexin B (Sakurai et al.
1998;A m m o u ne ta l .2003). Signal coupling of orexin
receptors has been rigorously investigated in few studies, the
vast majority of them was performed on cell lines recombi-
nantly expressing OX1Ro rO X 2R. OX1R primarily couples
via the Gq/11 subclass of G protein, while OX2Rc o u p l e st o
Gq/11,G s,a n dG i/o subclasses (Sakurai et al. 1998; van den
Pol et al. 1998; Randeva et al. 2001; Karteris and Randeva
2003; Kukkonen and Åkerman 2005; Ramanjaneya et al.
2009). One of the most marked responses to stimulation of
orexin receptors is a robust increase in intracellular Ca
2+
concentration, [Ca
2+]i, resulting from activation of two
pathways: receptor-operated Ca
2+ influx and phospholipase
C—inositol-(1,4,5)-trisphosphate/diacylglycerol (Sakurai et
al. 1998; Zhu et al. 2003; Holmqvist et al. 2005; Ekholm et
al. 2007; Gorojankina et al. 2007;T a n ge ta l .2008;r e v i e w e d
by Kukkonen and Åkerman 2005). A few reports suggest a
link between orexin receptors and the cyclic AMP pathway
(Zhu et al. 2003; Holmqvist et al. 2005; Magga et al. 2006;
Tang et al. 2008).
Although the expression pattern of the orexinergic system
in the CNS has been well characterized, little is known about
the presence of native orexin receptors and their signaling
system(s) in the primary neuronal cultures. In this study, we
investigated the expression of orexin receptors and the
intracellular mechanism followed the receptors’ activation
that can affect cyclic AMP formation in neuronal cell cultures
derived from rat cerebral cortex. We also determined which
type of orexin receptors is involved in this action. Our results
demonstrated that stimulation of OX2R inhibits cyclic AMP
production in a pertussin-toxin sensitive manner. This
suggests an involvement of Gi protein in coupling of
OX2Rt oa d e n y l y lc y c l a s e .
Materials and Methods
Animals and Cell Culture
Experiments were performed on primary neuronal cell
cultures prepared from Wistar rat embryos on day 16 of
gestation. Animal procedures were in strict accordance with
the Polish governmental regulations concerning experi-
ments on animals (Dz.U.05.33.289), and the experimental
protocol was approved by the Local Ethical Commission
for Experimentation on Animals.
Primary neuronal cell cultures were prepared according to
the method of Brewer (1995), described in detail by Nowak
and coworkers (2007). Briefly, pregnant females were
anesthetized with ether vapor, killed by decapitation, and
subjected to cesarean section in order to remove fetuses.
After brain’s dissection, the cerebral cortex was isolated,
incubated for 15 min in trypsin/EDTA (0.05%) at 37°C,
triturated in a solution of DNase I (0.05 mg/ml) and fetal
bovine serum (20%), and finally centrifuged at 210×g for
5 min at 21°C. The cells were suspended in neurobasal
medium supplemented with B27, 2 mM glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin and plated at a density
of 300,000–350,000 cells/well onto poly-L-ornithine
(0.01 mg/ml) coated multi-well plates. Cells were grown in
humidified atmosphere of 95% air and 5% CO2 at 37°C for
6–7 days prior to experimentation. Seventy-two hours after
plating the solution of 1-β-D-arabinofuranosylcytosine (a
final concentration—5 μM) was added to the neurobasal
medium to stop the glial proliferation. The purity of neuronal
cultures was verified by using antibodies against microtubule
associating protein-2 for neurons, and against glial fibrillary
acidic protein (GFAP), for astrocytes. The latter analysis
revealed the presence of approximately 6–10% of GFAP-
positive cells, which indicated that the primary neuronal
cultures represented in fact neuron-enriched preparations.
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TotalRNAwasextractedfromneuronalcellsbyusingTRIPure
Isolation Reagent (Roche, Meylan, France) according to the
manufacturer’s instruction. For each sample, total RNA (1 μg)
wassubjectedtoreversetranscription(RevertAidHMinusFirst
Strand cDNA Synthesis Kit, Fermentas, Burlington, Canada)
according to the manufacturer’s specifications.
Specific sense and antisense oligonucleotide primers for
amplification of mRNAs of rat OX1R and OX2R were
obtained from Invitrogen (Karlsruhe, Germany). The
sequences of specific primers and the procedure of real-
time quantitative PCR (qPCR) was published previously
(Jöhren et al. 2001). Shortly, 2 μl of first strand cDNA
reaction was incubated in the presence of 3 mM MgCl2;
200 μM of dGTP, dATP, dCTP, and dUTP; Platinum Taq
DNA Polymerase; the fluorescence dye SYBR green I; and
the appropriate sense and antisense primers in a final
volume of 25 μl (Platinum® SYBR® Green qPCR Super-
Mix, Invitrogen) on the 7000 Sequence Detection System
of Applied Biosystems (Darmstadt, Germany). Each sample
was analyzed in duplicate along with standards and no
template controls. Product purity was regularly confirmed
for each sample by dissociation curve analysis.
Copy number calculations were based on the cycle
threshold method (Higuchi et al. 1993). Serial dilutions of
known amounts of specific cDNA fragments were used to
generate standard curves. The threshold cycle number (CT)
for each sample was calculated using the 7000 Sequence
Detection System software with an automatic baseline
setting and a fluorescence threshold (Rn) of 0.2.
Assay of Cyclic AMP Formation
On the day of experiment, the culture medium was
removed, fresh serum-free culture medium was added, and
cells were incubated in the presence of [
3H]adenine for
30 min at 37°C. The formation of [
3H]cyclic AMP in [
3H]
adenine prelabeled cells was assayed according to Shimizu
et al. (1969), and the formed [
3H]cyclic AMP was isolated
by a sequential Dowex-alumina chromatography according
to Salomon et al. (1974). The results were individually
corrected for percentage recovery with the aid of [
14C]
cyclic AMP added to each column system prior to the
nucleotide extraction. The mean recovery was in the range
of 38–46%.The accumulation of cyclic AMP during a 15-min
stimulation period was assessed as a percentage of the
conversion of [
3H]adenine to [
3H]cyclic AMP. Antagonists
of orexin receptors were added 10-min prior to addition of
orexin A and [Ala
11-D-Leu
15]orexin B. All experiments were
carried out in the presence of 0.1 mM 3-isobuthyl-1-
methyxanthine (IBMX, an inhibitor of cyclic nucleotides’
phosphodiesterase). Pertussis toxin (PTX; 100 ng/ml) was
added 18 h prior to addition of orexin A. A day after addition
of pertussis toxin, the culture medium was removed and
fresh serum-free culture medium was added.
Chemicals
The peptides orexin A, [Ala
11-D-Leu
15]orexin B,
PACAP27 (human, ovine, and rat), and vasoactive intesti-
nal peptide (VIP; human, porcine, and rat) were from
NeoMPS (Strasbourg, France). N-(6,8-difluoro-2-methyl-4-
quinolinyl)-N′-[4-(dimethylamino)phenyl]urea (SB 408124)
and (2S)-1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-
3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanone
hydrochloride (TCS OX2 29), selective antagonists of OX1R
and OX2R, respectively, were purchased from Tocris
Bioscience (Bristol, UK). Forskolin, IBMX, poly-L-ornithine,
DNase I, trypsin, glutamine, penicillin, and streptomycin
were from Sigma-Aldrich (Poznan, Poland). Neurobasal
medium, B27, and fetal bovine serum were from Gibco
(Paisley, Scotland, UK). dGTP, dATP, dCTP, and dUTP, and
Platinum Taq DNA Polymerase were from Invitrogen
(Karlsruhe, Germany). Anti-neuronal class III β-tubulin
mouse monoclonal antibody, anti-glial fibrillary acidic
protein rabbit polyclonal antibody, Texas Red® dye-
conjugated goat anti-mouse antibody, and fluorescein
(FITC)-conjugated goat anti-rabbit antibody were purchased
from STEMCELL Technologies, Inc. (Vancouver, Canada).
Petri dishes and multi-well plates for cell cultures were from
Nunc (Wiesbaden, Germany). Radioactive compounds: [
3H]
adenine (sp. activity 24 Ci/mmol) and [
14C]cyclic AMP (sp.
activity 53 mCi/mmol) were from Hartmann-Analytic GmbH
(Braunschweig, Germany). Other chemicals were of analyti-
cal purity and were obtained mainly from Sigma-Aldrich
(Poznan, Poland).
Data Analysis
Data are expressed as mean ± standard error of the mean
(SEM) values and were analyzed for statistical significance
by one-way ANOVA followedby posthoc Student–Newman–
Keul’s test, using InStat version 3.05 for Windows 95
(GraphPad, San Diego, CA, USA).
Results
Expression of Orexin Receptors in the Primary Neuronal
Cell Cultures
Quantitative RT-PCR analysis with the use of specific
couples of primers demonstrated the expression of both
types of orexin receptors, OX1R and OX2R, in the primary
neuronal cell cultures derived from rat cerebral cortex.
12 J Mol Neurosci (2012) 46:10–17Interestingly, primary neuronal cells express about 24-fold
more OX2R than OX1R at the mRNA level (Fig. 1).
Effects of Orexin A and [Ala
11-D-Leu
15]Orexin B
on Cyclic AMP Formation in the Primary Neuronal Cells
No significant effects of orexin A (an agonist of OX1Ra n d
OX2R) and [Ala
11-D-Leu
15]orexin B (a selective agonist of
OX2R), both applied at 0.001–1 μM concentrations, on basal
cyclic AMP accumulation in cultured rat cortical neurons
were observed (data not shown). In line with previous
demonstrations (Jozwiak-Bebenista et al. 2007), incubation
of rat neuronal cell cultures with forskolin (a direct activator
of adenylyl cyclase; 1 μM), PACAP27 (0.1 μM), or VIP
(3 μM) resulted in a potent (three- to fivefold over the basal
level) increase in cyclic AMP production (Figs. 2, 3 and 4).
Orexin A and [Ala
11-D-Leu
15]orexin B (0.001–1 μM)
inhibited, in a concentration-dependent manner, the stimula-
tory action of forskolin, PACAP27, and VIP on cyclic AMP
formation in cultured rat cortical neurons (Fig. 2). The
calculated IC50 values for orexin A were: 24.5±1.8 nM
(experiments with forskolin), 26.3±1.4 nM (experiments
Fig. 1 Expression of orexin receptor subtypes OX1R and OX2Rb y
qPCR in rat cultured neurons. Shown are the specific RNA copy
numbers per nanograms of total RNA
Fig. 2 Effects of orexin A (an agonist of OX1Ra n dO X 2R) and [Ala
11-
D-Leu
15]orexin B (a selective agonist of OX2R) on cyclic AMP
formation in primary neuronal cell cultures from rat cerebral cortex
stimulated by forskolin (a), PACAP27 (b), and VIP (c). Values are
expressed as percent of the response to forskolin, PACAP27, and VIP,
and are means ± SEM (n=8–16). Cyclic AMP accumulation: experi-
ments with forskolin—control cultures, 0.86±0.12% conversion (n=18);
forskolin (1 μM) stimulated cultures, 3.39±0.22% conversion (n=20);
experiments with PACAP27—control cultures, 0.83±0.14% conversion
(n=16); PACAP27 (0.1 μM) stimulated cultures, 5.09±0.42% conver-
sion (n=24); experiments with VIP—control cultures, 0.88±0.15%
conversion (n=16); VIP (3 μM) stimulated cultures, 4.52±0.26%
conversion (n=20)

J Mol Neurosci (2012) 46:10–17 13with PACAP27), and 16.2±1.2 nM (experiments with VIP);
and for [Ala
11-D-Leu
15]orexin B: 42.0±2.0 nM (experiments
with forskolin), 32.3±1.9 nM (experiments with PACAP27),
and 22.9±1.6 nM (experiments with VIP).
Effects of OX1R and OX2R Antagonists on the Orexin
A-Induced Decrease in Cyclic AMP Formation
in the Primary Neuronal Cell Cultures
The observed by us similar potency of orexin A and [Ala
11-
D-Leu
15]orexin B suggested an involvement of OX2Ri n
the regulation of cyclic AMP synthesis in cultured rat
cortical neurons. In order to verify this hypothesis, in the
next set of experiments selective antagonists of OX1R (SB
408124) and OX2R (TCS 0X2 29) were used. TCS 0X2 29
(10 μM), but not SB 408124 (10 μM), blocked the
inhibitory actions of orexin A (1 μM) on increases of
cyclic AMP formation produced by forskolin, PACAP27,
and VIP (Fig. 3).
Effects of Pertussis Toxin on the Orexin A-Induced
Decrease in Cyclic AMP Formation in the Primary
Neuronal Cell Cultures
Pretreatment of rat neuronal cell cultures with pertussis
toxin (18 h, 100 ng/ml) did not affect the basal as well as
forskolin- and PACAP27-stimulated cyclic AMP accumu-
lation. Pertussis toxin abolished the inhibitory action of
orexin A on rises in the nucleotide formation produced by
forskolin and PACAP27 (Fig. 4).
Discussion
A number of studies, performed predominantly on trans-
fected cell lines, have demonstrated that orexin receptors
could interact with three families of G proteins, i.e., Gq/11,
Gs, and Gi/o, with different efficacies, and activate several
signaling pathways (e.g., Zhu et al. 2003; Holmqvist et al.
2005; Tang et al. 2008). The increase in [Ca
2+]i is the most
typical response seen in many cell types (de Lecea et al.
1998; Zhu et al. 2003; Ammoun et al. 2006; Magga et al.
2006;N ä s m a ne ta l2006; Gorojankina et al. 2007).
Regulation of adenylyl cyclase activity is also considered
as an important component of orexin receptors signaling
(Zhu et al. 2003; Holmqvist et al. 2005; Gorojankina et al.
2007; Tang et al. 2008), although this pathway has seldom
been investigated.
The results obtained in the present study provide
evidence that in the primary neuronal cell cultures from
rat cerebral cortex expression of OX2R is considerably
higher than that of OX1R. Our further studies on the
primary astrocyte cultures from rat brain identified similar
expressions of both types of orexin receptors at the mRNA
level; however, they were markedly lower compared to
neuronal cell cultures (unpublished data). This suggests that
Fig. 3 a–c TCS OX2 29 (TCS,1 0μM), a selective antagonist of
OX2R, but not SB 408124 (SB,1 0μM), a selective antagonist of
OX1R, blocked the inhibitory action of orexin A (1 μM) on forskolin
(1 μM), PACA27 (0.1 μM), and VIP (3 μM) induced increase in
cyclic AMP formation in primary neuronal cell cultures from rat
cerebral cortex. Values shown are means ± SEM (n=8–15).
aP<0.05
versus control,
bP<0.05 versus stimulatory agent (Forskolin,
PACAP27, or VIP);
cP<0.05 versus stimulatory agent and orexin
14 J Mol Neurosci (2012) 46:10–17in the rat cerebral cortex the expression of orexin receptors
is closely related to the cell type, and may trigger distinct
cellular responses. To test this hypothesis we evaluated a
potential role of the orexin receptors’ activation in the
regulation of cyclic AMP production in neurons. Treatment
of cortical neuronal cultures with orexin A (the nonselective
agonists of OX1R and OX2R) and [Ala
11-D-Leu
15]orexin B
(the selective OX2R agonist; Asahi et al. 2003) failed to
significantly affect the basal cyclic AMP accumulation
suggesting that orexin receptors expressed in this cell type
do not couple to the Gs subclass of G protein. On the other
hand, orexin A and [Ala
11-D-Leu
15]orexin B potently
inhibited, in a concentration-dependent manner, cyclic
AMP production stimulated by the diterpene forskolin, the
direct activator of adenylyl cyclase, and by two neuro-
peptides, i.e., PACAP and VIP, well-known activators of Gs
proteins (Vaudry et al. 2009). The calculated IC50 values for
both peptides were in low, nanomolar range, suggesting that
this inhibition is of physiological relevance. Two lines of
evidence point to the involvement of OX2R in the studied
phenomenon. Firstly, [Ala
11-D-Leu
15]orexin B was almost
equipotent to orexin A. Secondly, the inhibitory action of
orexin A was blocked by TCS 0X2 29, the selective OX2R
antagonist (Hirose et al. 2003), and not affected by SB
408124, the selective OX1R antagonist (Porter et al. 2001).
Pertussis toxin, which deactivates Gi/Go through ADP
Fig. 4 Pretreatment of rat corti-
cal neuron cultures with pertus-
sis toxin (PTX; 18 h, 100 ng/ml)
abolished the inhibitory action
of orexin A (1 μM) on forskolin
(1 μM) and PACAP27 (0.1 μM)
induced increase in cyclic AMP
formation. Values shown are
means ± SEM (n=9–12).
aP<0.05 versus control,
bP<0.05 versus Forskolin or
PACAP27,
cP<0.05 versus
Forskolin or PACAP27
and orexin A
J Mol Neurosci (2012) 46:10–17 15ribosylation, abolished the inhibitory effect of orexin A on
stimulated cyclic AMP production. Hence, it would appear
that this effect is mediated by OX2R-coupling to Gi protein.
A functional coupling between Gi/o proteins and OX2R has
been previously demonstrated in HEK293 and BIM cell
lines heterologously expressing human OX2R (Hoang et al.
2003; Zhu et al. 2003; Tang et al. 2008).
In the context of the present study it is interesting to note
that our previous results in astrocyte cultures from rat cerebral
cortex demonstrated a stimulatory effect of orexin A, but not
[Ala
11-D-Leu
15]orexin B, on cyclic AMP synthesis indicat-
ing a predominant OX1R involvement in this action
(Woldan-Tambor et al. 2011). Thus, it could be hypothesized
that depending on a cell type in the rat cerebral cortex the
biochemical responses to the tested peptides are mediated via
different types of receptors interacting with distinct families
of G proteins. It would be highly interesting to know
whether the orexinergic system in astrocyte compartment in
the rat brain can affect neuronal functions.
A physiological significance of the OX2R-trigerred
intracellular signaling, including cyclic AMP pathway, in
rat cortical neurons is yet to be evaluated. Studies on
HEK293-OX2R cells suggested that adenylyl cyclase–
cyclic AMP pathway is, in part, functionally linked to the
activation by orexins of extracellular signal-regulated
kinase (ERK1/2) and p38 mitogen-activated protein kinase
(p38 MAPK) (Tang et al. 2008). This hypothesis appears
particularly interesting in light of the well-known involve-
ment of MAPK signaling pathways in the regulation of cell
growth, differentiation, and gene expression.
In conclusion, the results presented here demonstrate that
in cultured rat cortical neurons orexins, acting at OX2
receptors coupled to PTX-sensitive Gi protein, inhibit cyclic
AMP synthesis.
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